Page last updated: 2024-08-24

venlafaxine hydrochloride and medroxyprogesterone acetate

venlafaxine hydrochloride has been researched along with medroxyprogesterone acetate in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	1 (33.33)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Barton, D; Bearden, JD; Dakhil, SR; Fitch, TR; Kugler, JW; Levitt, R; Loprinzi, CL; Mailliard, JA; Nikcevich, DA; Sloan, JA; Tschetter, LK	1
Bouchard, P; Irani, J; Mottet, N; Oba, R; Salomon, L	1
Crandall, CJ; Manson, JE; Mehta, JM	1

Reviews

1 review(s) available for venlafaxine hydrochloride and medroxyprogesterone acetate

Article	Year
Management of Menopausal Symptoms: A Review. JAMA, 2023, 02-07, Volume: 329, Issue:5 Topics: Autonomic Nervous System Diseases; Estrogen Replacement Therapy; Estrogens; Estrogens, Conjugated (USP); Female; Female Urogenital Diseases; Hot Flashes; Humans; Medroxyprogesterone Acetate; Menopause; Neoplasms; Paroxetine; Sweating; Venlafaxine Hydrochloride; Venous Thromboembolism	2023

Trials

2 trial(s) available for venlafaxine hydrochloride and medroxyprogesterone acetate

Article	Year
Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Mar-20, Volume: 24, Issue:9 Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents, Hormonal; Cyclohexanols; Drug Therapy, Combination; Female; Hot Flashes; Humans; Medroxyprogesterone Acetate; Menopause; Middle Aged; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride	2006
Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial. The Lancet. Oncology, 2010, Volume: 11, Issue:2 Topics: Adenocarcinoma; Androgen Antagonists; Autonomic Agents; Cyclohexanols; Cyproterone Acetate; Double-Blind Method; Gonadotropin-Releasing Hormone; Hot Flashes; Humans; Male; Medroxyprogesterone Acetate; Prospective Studies; Prostatic Neoplasms; Treatment Outcome; Venlafaxine Hydrochloride	2010

Article

Year

Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Mar-20, Volume: 24, Issue:9

Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents, Hormonal; Cyclohexanols; Drug Therapy, Combination; Female; Hot Flashes; Humans; Medroxyprogesterone Acetate; Menopause; Middle Aged; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride

2006

Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial.

The Lancet. Oncology, 2010, Volume: 11, Issue:2

Topics: Adenocarcinoma; Androgen Antagonists; Autonomic Agents; Cyclohexanols; Cyproterone Acetate; Double-Blind Method; Gonadotropin-Releasing Hormone; Hot Flashes; Humans; Male; Medroxyprogesterone Acetate; Prospective Studies; Prostatic Neoplasms; Treatment Outcome; Venlafaxine Hydrochloride

2010